Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Cash Flow (Unaudited)

v2.4.1.9
Condensed Consolidated Statement of Cash Flow (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities    
Net loss for the period $ (1,321,799)us-gaap_NetIncomeLoss $ (595,600)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued interest and dividends on marketable securities 7,156aker_AccruedInterestAndDividendsOnMarketableSecurities   
Depreciation and amortization 80,349us-gaap_DepreciationDepletionAndAmortization 86,825us-gaap_DepreciationDepletionAndAmortization
Gain from other non-operating activities (5,355)aker_GainLossFromOtherNonoperatingActivities (4,669)aker_GainLossFromOtherNonoperatingActivities
Changes in assets and liabilities    
(Increase)/decrease in trade receivables 20,041us-gaap_IncreaseDecreaseInAccountsReceivable (20,197)us-gaap_IncreaseDecreaseInAccountsReceivable
Increase in trade receivables - related party    (266,379)us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties
Decrease in notes receivables - related party 43,491us-gaap_IncreaseDecreaseInNotesReceivableRelatedParties   
(Increase)/decrease in other receivables 14,985us-gaap_IncreaseDecreaseInOtherReceivables (30,697)us-gaap_IncreaseDecreaseInOtherReceivables
(Increase)/decrease in inventories (64,786)us-gaap_IncreaseDecreaseInInventories 359,996us-gaap_IncreaseDecreaseInInventories
(Increase)/decrease in other assets (20,470)us-gaap_IncreaseDecreaseInOtherOperatingAssets 118,698us-gaap_IncreaseDecreaseInOtherOperatingAssets
Increase/(decrease) in trade and other payables 87,745us-gaap_IncreaseDecreaseInAccountsPayableTrade (390,428)us-gaap_IncreaseDecreaseInAccountsPayableTrade
Decrease in other payables - related party    (6,586)us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties
Decrease in deferred revenue - related party (83,333)us-gaap_IncreaseDecreaseInDeferredRevenue (83,333)us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash used in operating activities (1,241,975)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (832,370)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities    
Purchases of property, plant and equipment (44,510)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment   
Purchases of marketable securities (27,228)us-gaap_PaymentsToAcquireMarketableSecurities (12,508,984)us-gaap_PaymentsToAcquireMarketableSecurities
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture (64,675)us-gaap_PaymentsToAcquireInterestInJointVenture   
Proceeds from demutualization of insurance carrier    4,669us-gaap_ProceedsFromInsuranceSettlementInvestingActivities
Proceeds from other non-operating activities 5,355aker_ProceedsFromOtherNonoperatingActivities   
Proceeds from sale of marketable securities 1,253,436us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities   
Net cash provided by/(used in) investing activities 1,122,378us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (12,504,315)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities    
Payment of short-term note payable - related party    (307,500)us-gaap_RepaymentsOfShortTermDebt
Proceeds from issuance of common shares    745,024us-gaap_ProceedsFromIssuanceOfCommonStock
Net proceeds from issuance of common stock in initial public offering    13,101,336us-gaap_ProceedsFromIssuanceInitialPublicOffering
Net cash provided by financing activities    13,538,860us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net increase/(decrease) in cash (119,598)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 202,175us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash at beginning of period 455,841us-gaap_CashAndCashEquivalentsAtCarryingValue 103,634us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash at end of period 336,243us-gaap_CashAndCashEquivalentsAtCarryingValue 305,809us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Unrealized gains/(losses) on marketable securities 26,713us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax (10,874)us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
Issuance of restricted common share grants to directors and officers accrued in 2014 $ 697,300aker_IssuanceOfRestrictedCommonShareGrantsToDirectorsAndOfficersAccruedValue